- Home
- CCCC vs BYRN Comparison
CCCC vs BYRN Comparison
Compare CCCC & BYRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCC
- BYRN
- Stock Information
- Founded
- CCCC 2015
- BYRN 2005
- Country
- CCCC United States
- BYRN United States
- Employees
- CCCC N/A
- BYRN N/A
- Industry
- CCCC Biotechnology: Pharmaceutical Preparations
- BYRN Industrial Machinery/Components
- Sector
- CCCC Health Care
- BYRN Miscellaneous
- Exchange
- CCCC Nasdaq
- BYRN Nasdaq
- Market Cap
- CCCC 104.4M
- BYRN 670.5M
- IPO Year
- CCCC 2020
- BYRN N/A
- Fundamental
- Price
- CCCC $1.48
- BYRN $32.50
- Analyst Decision
- CCCC Buy
- BYRN Strong Buy
- Analyst Count
- CCCC 3
- BYRN 2
- Target Price
- CCCC $12.00
- BYRN $36.00
- AVG Volume (30 Days)
- CCCC 1.4M
- BYRN 560.8K
- Earning Date
- CCCC 07-31-2025
- BYRN 07-10-2025
- Dividend Yield
- CCCC N/A
- BYRN N/A
- EPS Growth
- CCCC N/A
- BYRN N/A
- EPS
- CCCC N/A
- BYRN 0.61
- Revenue
- CCCC $39,783,000.00
- BYRN $95,292,000.00
- Revenue This Year
- CCCC N/A
- BYRN $37.49
- Revenue Next Year
- CCCC N/A
- BYRN $21.56
- P/E Ratio
- CCCC N/A
- BYRN $54.06
- Revenue Growth
- CCCC 98.56
- BYRN 87.26
- 52 Week Low
- CCCC $1.09
- BYRN $7.79
- 52 Week High
- CCCC $7.66
- BYRN $34.78
- Technical
- Relative Strength Index (RSI)
- CCCC 48.83
- BYRN 63.74
- Support Level
- CCCC $1.36
- BYRN $29.75
- Resistance Level
- CCCC $1.60
- BYRN $32.50
- Average True Range (ATR)
- CCCC 0.12
- BYRN 1.80
- MACD
- CCCC -0.00
- BYRN -0.12
- Stochastic Oscillator
- CCCC 31.58
- BYRN 90.62
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
About BYRN Byrna Technologies Inc.
Byrna Technologies Inc is a designer, manufacturer, retailer, and distributor of technological solutions for security situations that do not require the use of lethal force. The company generates its revenue from the United States, South Africa, Europe, South America, Asia, and Canada.